Management of Generalized Pruritus Unresponsive to Cetirizine

1. Assessment and Investigation

Perform a complete blood count to screen for hematologic malignancy, iron deficiency, or polycythemia vera in patients with generalized itching unresponsive to cetirizine. 3
Order a comprehensive metabolic panel to evaluate renal and hepatic function as potential systemic contributors. 3
Include liver function tests and, when hepatic disease is suspected, assess bile acids and antimitochondrial antibodies. 3, 4
Reserve thyroid‑function testing for patients with additional endocrine‑related signs or symptoms. 3
Conduct HIV and hepatitis A‑B‑C serology in individuals with relevant risk factors or travel history. 3, 5
Screen for parasitic infections (e.g., malaria, strongyloidiasis, schistosomiasis) when travel exposure warrants investigation. 3, 5

Apply emollients as the foundational skin‑care measure. 2, 6
Use topical doxepin for up to 8 days, limited to ≤10 % body‑surface area and a maximum of 12 g per day. 2, 7
Consider topical clobetasone butyrate or menthol for additional symptomatic relief. 2, 7

Offer non‑sedating antihistamines at higher doses (e.g., fexofenadine 180 mg or loratadine 10 mg) as a systemic option. 7
Avoid long‑term use of sedating antihistamines because of an increased risk of dementia, except in palliative contexts. 1, 2

Optimize dialysis adequacy, correct calcium‑phosphate imbalance, and control parathyroid hormone levels. 8, 6, 5
Treat anemia with erythropoietin‑stimulating agents. 1, 8
Maintain skin hydration with emollients for xerosis. 1, 8
Prescribe gabapentin 100–300 mg after dialysis, three times weekly (lower dose than in non‑ESRD patients). 1, 4
Use topical capsaicin cream or calcipotriol as adjunctive agents. 1, 2, 8
Consider broadband UVB (BB‑UVB) phototherapy (strength of recommendation A). 2, 8, 5
Auricular acupressure or aromatherapy may be offered as complementary measures. 2, 8

Initiate rifampicin as first‑line therapy (strength A). 2, 8, 5
If rifampicin fails, step to cholestyramine as second‑line treatment. 2, 8, 5, 7
Use sertraline as a third‑line option before considering opioid antagonists. 2, 8, 5, 7
Reserve naltrexone or nalmefene for fourth‑line management. 2, 6, 7
Fifth‑line agents include dronabinol, phenobarbitone, propofol, or topical tacrolimus. 2, 6, 7
Gabapentin is contraindicated in hepatic pruritus. 2, 8, 5

Therapeutic options include cimetidine, carbamazepine, gabapentin, or mirtazapine. 8, 6, 5
Oral corticosteroids may be used when lymphoma is incurable. 8, 6, 5
NB‑UVB or BB‑UVB phototherapy can provide symptomatic relief. 8, 6, 5

Manage with cytoreductive therapy, aspirin, interferon‑α, SSRIs, cimetidine, or atenolol. 8, 6, 5
Phototherapy (NB‑UVB, BB‑UVB, PUVA) is effective but relapse is common after discontinuation. 8, 6, 5

Discontinue the suspected offending medication when the risk‑benefit assessment permits. 3, 8, 5
For opioid‑induced itch, use naltrexone as first‑choice; alternatives include methylnaltrexone, ondansetron, droperidol, mirtazapine, or gabapentin. 2, 6, 7

Refer to secondary care when diagnostic uncertainty persists or when primary‑care management fails to control symptoms. 2, 6

All bullet points are supported by the cited references indicated in brackets.